Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Fusen Pharmaceutical Co., Ltd. ( (HK:1652) ) has provided an update.
Fusen Pharmaceutical Co., Ltd. announced that its subsidiary, Jiaheng Pharmaceutical Technology, has received approval from the National Medical Products Administration of the PRC to market ‘Measartan Potassium Tablets’ for treating primary hypertension. This product, containing azilsartan medoxomil potassium, enhances the company’s portfolio in the blood circulatory system field, offering a new treatment option for hypertension with significant and stable effects, and aligns with the company’s strategy to strengthen its market position in the antihypertensive drug sector.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
More about Fusen Pharmaceutical Co., Ltd.
Fusen Pharmaceutical Co., Ltd. is a company incorporated in the Cayman Islands, focusing on the pharmaceutical industry. The company, along with its subsidiaries, develops and markets medical products, with a particular emphasis on treatments for the blood circulatory system.
Average Trading Volume: 2,542,245
Technical Sentiment Signal: Buy
Current Market Cap: HK$602.9M
For detailed information about 1652 stock, go to TipRanks’ Stock Analysis page.